SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $929 | -96.9% | 64 | -95.5% | 0.00% | – |
| Q2 2023 | $29,972 | +166411.1% | 1,432 | +68.1% | 0.00% | – |
| Q1 2023 | $18 | +1700.0% | 852 | +1928.6% | 0.00% | – |
| Q4 2022 | $1 | -99.9% | 42 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -97.4% | 42 | -98.1% | 0.00% | – |
| Q1 2022 | $38,000 | +8.6% | 2,160 | 0.0% | 0.00% | – |
| Q4 2021 | $35,000 | -23.9% | 2,160 | -10.0% | 0.00% | – |
| Q3 2021 | $46,000 | +12.2% | 2,400 | 0.0% | 0.00% | – |
| Q2 2021 | $41,000 | +272.7% | 2,400 | +380.0% | 0.00% | – |
| Q1 2021 | $11,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2020 | $11,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |